Why Every Man Should Take Sildenafil & Tadalafil (even with good erections)

Key wellness strategies & self-care / productivity tips discussed

Proactive erectile health support (especially around midlife)

• A healthy ~40-year-old man may consider starting regular PDE5 inhibitor use (e.g., sildenafil or tadalafil) to help protect long-term erectile function.
• For younger, perfectly healthy men (e.g., ~25), the concern is less about physical damage and more about psychological dependence—feeling able to perform only when on the medication.

Use PDE5 inhibitors strategically for confidence restoration (not just performance)

• The speaker describes a “confidence restoration” approach for men with psychogenic ED who have normal hormones and vasculature.
• Reported outcome: ~90% of men in relationships can be off pills long-term (as described in the published paper).
• Relationship context matters:
  • In a stable, loving relationship, confidence tends to return.
  • In single dating/situationship cycles, new partners add stress (“adrenaline generator”), making confidence restoration harder.

An underused high-success treatment: intracavernosal injections

• Intracavernosal injections are described as very effective for erectile dysfunction, especially post–prostate cancer surgery.
• Practical mechanism summary: vasodilator drugs injected directly into the penile shaft.

Injection safety & realistic expectations

• Main risk mentioned: priapism (an erection that won’t go away).
• The speaker reports low rates in a well-monitored program (e.g., ~0.2% in their setting).

Improve results by avoiding common injection mistakes

• Poor injection technique (wrong angle/depth, timing errors).
• Self-adjusting dose without guidance (dose increases are associated with worse outcomes).
• Trying to inject too frequently in short intervals—though it’s suggested that with proper monitoring/knowledge this can be managed.

Plan around medication stability (refrigeration logistics)

• Some injection drugs lose potency over time at room temperature and require refrigeration.
• Practical workaround:
  • Pre-fill syringes for a short trip/weekend to avoid repeated temperature exposure.
  • Use an alternative medication formulation when refrigeration is difficult.

ED risk after prostate cancer is multifactorial

Outcomes depend on:

• Age
• Baseline erectile function (e.g., diabetes can worsen the starting point)
• Nerve-sparing quality during surgery
• Radiation dose
• Androgen deprivation therapy (ADT) duration/type

Key point:

• Long-term testosterone suppression can harm erectile tissue; men on long-term ADT often won’t respond well to PDE5 inhibitors and may require injections.

“Reasonable” modern estimate after prostate cancer treatment (general)

• After prostatectomy or radiation, the speaker suggests roughly a 50–60% chance of recovery/response within ~2 years (with PDE5 inhibitor response described as roughly similar).
• For different combinations (nerve-sparing quality, ADT duration, non–nerve-sparing approaches), predictions become much harder.

Patient empowerment / shared decision-making

The speaker encourages patients to:

• Ask about nerve-sparing odds (surgeon)
• Ask about ADT role and duration (radiation oncologist)
• Decide based on what matters most to them (e.g., survival benefit timing vs. quality of life)

Mental framing:

• Avoid “doctor-only decisioning”—practice actively deciding for oneself.

Emerging “focused therapies” (promising but limited evidence)

• Focused ultrasound and cryotherapy were discussed as not yet supported by sufficient long-term studies.
• Hemi-gland ablation (half-gland) may preserve erectile function for some compared with more extensive approaches, but whole-gland treatments may have ED rates closer to standard options.

Ejaculation-sparing treatments still carry ejaculatory risk

• Men seeking ejaculation/ejaculatory sparing may still experience dysfunction because the ejaculatory ducts are very close to each other and therapies can affect the surrounding millimeters.

Differentiate ejaculation vs orgasm (important for expectations)

• Ejaculation = semen release
• Orgasm = pleasure/climax (primarily cerebral; supported by pelvic muscle contractions)

Reported observations:

• Many post-prostatectomy patients may have reduced ejaculation but can still experience orgasm.
• Some men report different orgasm intensity after surgery:
  • Most: less intensity
  • Some: same intensity
  • Smaller group: more intense

Concept introduced:

• “Ejaculatory distress”: a subset of men are strongly bothered about no longer ejaculating.

---

Presenters / sources

Individuals mentioned

• Al Shenkin (paper first author; fellow of the speaker; now at LAN as stated in subtitles)

Credit for injection therapy history (names appear distorted)

• Ronald/“Ron” Vagin? (subtitle appears corrupted; referenced as a vascular surgeon experimenting with an injection that produced erection)
• William/“Chap Jes” Brindley (UK; described in 1982; used phentolamine/“phoxy Benz” as transcribed)

FDA-approved drugs mentioned (PDE5 inhibitors; names unclear)

• Edex and Cabaj (exact names unclear due to subtitle errors; referenced as FDA-approved injection options)

Clinical affiliations mentioned (name unclear due to subtitle errors)

• Memorial (hospital/center referenced; exact full name unclear)

Other contributors

• Cardiologist (conference speaker; name not provided)

Note: Several names and drug spellings likely appear distorted by auto-generated subtitles. If you want, I can produce a “best-guess correction” table for the uncertain items.